Furanocoumarins Are a Novel Class of Modulators for the Transient Receptor Potential Vanilloid Type 1 (TRPV1) Channel*

Xingjuan Chen,Weiyang Sun,N. Gianaris,Ashley M. Riley,T. Cummins,J. Fehrenbacher,A. Obukhov

Published 2014 in Journal of Biological Chemistry

ABSTRACT

Background: Furanocoumarin imperatorin is a major active component of Angelica dahurica root extracts exhibiting analgesic properties. Results: Imperatorin inhibited formalin- and capsaicin-induced nocifensive responses, facilitated TRPV1 desensitization, and sensitized TRPV1 to acid activation. Conclusion: Furanocoumarins represent a novel class of TRPV1 partial agonists exhibiting analgesic potential. Significance: Imperatorin is a lead compound for drug discovery aimed at developing new analgesics. Furanocoumarin imperatorin is the major active component of Angelica dahurica root extracts, widely used in traditional medicine to treat headache, toothache, and orbital eye pain. In this study, we investigated the mechanisms that may underlie the pain-relieving effects of the compound. We found that imperatorin significantly inhibited formalin- and capsaicin-induced nocifensive responses but did not alter baseline thermal withdrawal thresholds in the rat. We established that imperatorin is a weak agonist of TRPV1, a channel implicated in detecting several noxious stimuli, exhibiting a 50% effective concentration (EC50) of 12.6 ± 3.2 μm. A specific TRPV1 antagonist, JNJ-17203212 (0.5 μm), potently inhibited imperatorin-induced TRPV1 activation. Site-directed mutagenesis studies revealed that imperatorin most likely acted via a site adjacent to or overlapping with the TRPV1 capsaicin-binding site. TRPV1 recovery from desensitization was delayed in the presence of imperatorin. Conversely, imperatorin sensitized TRPV1 to acid activation but did not affect the current amplitude and/or the activation-inactivation properties of Nav1.7, a channel important for transmission of nociceptive information. Thus, our data indicate that furanocoumarins represent a novel group of TRPV1 modulators that may become important lead compounds in the drug discovery process aimed at developing new treatments for pain management.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-44 of 44 references · Page 1 of 1

CITED BY

Showing 1-53 of 53 citing papers · Page 1 of 1